Sign in Register

Drug class

Beta-Blockers (Systemic)

Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body. Read more about Beta-Blockers (Systemic)

386 drugs in this class 143 manufacturers

Related classes & indications

Calcium Channel BlockersCardiovascular & renal · 344 prescription drugs Angiotensin II Receptor Antagonists (ARBs)Cardiovascular & renal · 281 prescription drugs HypertensionTop indication · 1,834 prescription drugs

Showing 37–45 of 386 drugs

Sort

CARVEDILOL

ALPHA-BETA BLOCKERS · HYPERTENSION ·+2

Mylan Pharmaceuticals

CARVEDILOL

ALPHA-BETA BLOCKERS · HYPERTENSION ·+2

SANDOZ

CARVEDILOL

ALPHA-BETA BLOCKERS · HYPERTENSION ·+2

DR.REDDY'S LAB

CARVEDILOL

ALPHA-BETA BLOCKERS · HYPERTENSION ·+2

GLENMARK PHARMA

CARVEDILOL

ALPHA-BETA BLOCKERS · HYPERTENSION ·+2

ZYDUS PHARMACEU

CARVEDILOL

ALPHA-BETA BLOCKERS · HYPERTENSION ·+2

Major Pharamceuticals

CARVEDILOL

ALPHA-BETA BLOCKERS · HYPERTENSION ·+2

AUROBINDO PHARM

CARVEDILOL

ALPHA-BETA BLOCKERS · HYPERTENSION ·+2

SOLCO HEALTHCAR

CARVEDILOL

ALPHA-BETA BLOCKERS · HYPERTENSION ·+2

MYLAN INSTITUTI

Filter & compare in the drug finder → Opens the drug finder with Beta-Blockers (Systemic) preselected. Add indication or manufacturer filters there.

About Beta-Blockers (Systemic).

Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body.

By blocking cardiac beta-1 and peripheral beta-2 receptors, these medications exert negative inotropic and chronotropic effects, slowing the heart rate, decreasing myocardial contractility, and lowering systemic arterial blood pressure.

They are primarily indicated across cardiovascular medicine for the management of hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction, and chronic heart failure with reduced ejection fraction.

Additionally, systemic beta-blockers play key therapeutic roles in non-cardiovascular conditions, including migraine prophylaxis, essential tremor, and the symptomatic management of thyrotoxicosis.

fda.gov
Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body By blocking cardiac beta-1 and peripheral beta-2 receptors, these medications exert negative inotropic and chronotropic effects, slowing the heart rate, decreasing myocardial contractility, and lowering systemic arterial blood pressure
nih.gov
Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body
nih.gov
By blocking cardiac beta-1 and peripheral beta-2 receptors, these medications exert negative inotropic and chronotropic effects, slowing the heart rate, decreasing myocardial contractility, and lowering systemic arterial blood pressure They are primarily indicated across cardiovascular medicine for the management of hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction, and chronic heart failure with reduced ejection fraction Additionally, systemic beta-blockers play key ther...
mayoclinic.org
By blocking cardiac beta-1 and peripheral beta-2 receptors, these medications exert negative inotropic and chronotropic effects, slowing the heart rate, decreasing myocardial contractility, and lowering systemic arterial blood pressure
nih.gov
They are primarily indicated across cardiovascular medicine for the management of hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction, and chronic heart failure with reduced ejection fraction
clevelandclinic.org
They are primarily indicated across cardiovascular medicine for the management of hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction, and chronic heart failure with reduced ejection fraction Additionally, systemic beta-blockers play key therapeutic roles in non-cardiovascular conditions, including migraine prophylaxis, essential tremor, and the symptomatic management of thyrotoxicosis